Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced the annualized asthma exacerbation rate (AAER) by 56% versus placebo in patients with severe, uncontrolled asthma. This pre-specified, exploratory analysis evaluated the efficacy of tezepelumab in NAVIGATOR patients grouped by number of perennial aeroallergen sensitivities as determined by serum-specific immunoglobulin (Ig)E testing at baseline.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
